Do you want to read an article? Please log in or register.
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
Gynecologic Cancer
RECOMMENDED
Related content
Genitourinary Cancer
Use of First-Line PARP Inhibitors in Ovarian Cancer
healthbook TIMES Oncology Hematology
Hasler-Strub U.
doi: 10.36000/hbT.OH.2019.02.006
Gynecologic Cancer
The forefront of ovarian cancer therapy: update on PARP inhibitors
Ann Oncol.
Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S
doi: 10.1016/j.annonc.
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer
Ann Oncol.
Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodriguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V
doi: 10.1093/annonc/mdy099.
Gynecologic Cancer
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials
Cancer Treat Rev.
Ruscito I, Bellati F, Ray-Coquard I, Mirza MR, du Bois A, Gasparri ML, Costanzi F, De Marco MP, Nuti M, Caserta D, Pignata S, Dorigo O, Sehouli J, Braicu EI
doi: 10.1016/j.ctrv.2020.102040.
Gynecologic Cancer
Ovarian cancer specific BRCA-like copy number aberration classifiers detect mutations associated with homologous recombination deficiency in the AGO-TR1 trial
Clin Cancer Res
Schouten PC, Richters LK, Vis DJ, Kommoss S, van Dyk E, Ernst C, Kluin RJC, Marme F, Lips EH, Schmidt S, Scheerman E, Prieske K, van Deurzen CHM, Burges A, Ewing-Graham PC, Dietrich D, Jager A, de Gregorio N, Hauke J, du Bois A, Nederlof PM, Wessels LF, Hahnen E, Harter P, Linn SC, Schmutzler RK
doi: 10.1158/1078-0432.CCR-21-1673
Further Publications
Precision Oncology for Hepato-Pancreato-Biliary (HPB) Cancers: State of the Art and Future Directions
★ 3
Recommended and commented by
Alexander Meisel, Faculty Member
1Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
*equal contribution
Breast Cancer
Breast Cancer Treatment in the Era of Precision Medicine
1Breast Cancer Center, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland
RECOMMENDED
Gynecologic Cancer
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC
doi: 10.1200/JCO.20.01924.
RECOMMENDED
Breast Cancer
TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol.
Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff AC, Winer EP
doi: 10.1016/j.annonc.2020.08.2064.